Alkermes plc - Ordinary Shares (NQ:ALKS)

50.80 -1.92 (-3.65%)

Streaming Delayed Price Updated: 9:58 AM EDT, Jul 28, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Alkermes plc - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Alkermes Q2 Earnings Call Highlights ↗

Today 10:04 EDT

Alkermes (NASDAQ:ALKS) reported second-quarter 2026 revenue of $496 million, supported by growth across its proprietary product portfolio and the first full-quarter contribution from LUMRYZ following...

Via MarketBeat

Topics Earnings

Alkermes (NASDAQ:ALKS) Reports Quality Earnings Beat but Stock Falls on Lack of Guidance ↗

Today 8:20 EDT

Via Chartmill

Topics Earnings

Alkermes plc Reports Second Quarter 2026 Financial Results

Today 7:00 EDT

From Alkermes plc

Via Business Wire

Alkermes to Report Second Quarter Financial Results on July 28, 2026

July 14, 2026

From Alkermes plc

Via Business Wire

Alkermes plc (NASDAQ:ALKS) Reports Mixed Q1 Results, Beats Revenue Forecasts but Posts Wider Than Expected Loss ↗

May 05, 2026

Via Chartmill

Alkermes Plc (NASDAQ:ALKS) Shows Strong Technical Setup with High Breakout Potential ↗

April 29, 2026

Via Chartmill

Alkermes PLC (NASDAQ:ALKS) Reports Strong Q4 Earnings Beat Amid Muted Market Reaction ↗

February 25, 2026

Via Chartmill

Topics Earnings

Alkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis

July 13, 2026

From Alkermes plc

Via Business Wire

Alkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026

June 17, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe

June 15, 2026

From Alkermes plc

Via Business Wire

Alkermes Touts Orexin Ambitions as Alixorexton Enters Phase 3 and CEO Transition Nears ↗

June 10, 2026

Alkermes (NASDAQ:ALKS) executives said the company is entering a period of heightened execution as it advances its orexin agonist program into late-stage development, integrates Avadel and prepares for...

Via MarketBeat

Alkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research

June 04, 2026

From Alkermes plc

Via Business Wire

Alkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference

June 03, 2026

From Alkermes plc

Via Business Wire

Alkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting

May 26, 2026

From Alkermes plc

Via Business Wire

Alkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences

May 21, 2026

From Alkermes plc

Via Business Wire

Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia

May 12, 2026

From Alkermes plc

Via Business Wire

Alkermes (ALKS) Q1 2026 Earnings Transcript ↗

May 05, 2026

Alkermes (ALKS) Q1 2026 Earnings Transcript

Via The Motley Fool

Alkermes plc Reports First Quarter 2026 Financial Results

May 05, 2026

From Alkermes plc

Via Business Wire

Alkermes to Report First Quarter Financial Results on May 5, 2026

April 21, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting

April 16, 2026

From Alkermes plc

Via Business Wire

Findings From Long-Term Analysis of the Effects of LYBALVI® (olanzapine and samidorphan) on Negative Symptoms of Schizophrenia Published in The Journal of Clinical Psychiatry

April 14, 2026

From Alkermes plc

Via Business Wire

Lilly’s $7.8 Billion Centessa Bet: Inside the Race to Dominate the Sleep Market’s ‘Orexin Gold Rush’

April 06, 2026

On March 31, 2026, Eli Lilly and Company (NYSE:LLY) sent shockwaves through the biotechnology sector by announcing a definitive agreement to acquire Centessa Pharmaceuticals (Nasdaq:CNTA) for a total...

Via MarketMinute

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2

April 01, 2026

From Alkermes plc

Via Business Wire

The Orexin Gold Rush: Deep Dive into Eli Lilly’s $7.8 Billion Acquisition of Centessa Pharmaceuticals

March 31, 2026

Today, March 31, 2026, the biotechnology landscape has been fundamentally reshaped. Eli Lilly and Company (NYSE: LLY) has officially announced a definitive agreement to acquire Centessa Pharmaceuticals...

Via Finterra

Topics Economy Initial Public Offering Intellectual Property

Alkermes Announces Inaugural Alkermes Pathways APN Research Awards™ Program

March 12, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the Stifel 2026 Virtual CNS Forum

March 10, 2026

From Alkermes plc

Via Business Wire

Alkermes (ALKS) Q4 2025 Earnings Call Transcript ↗

February 25, 2026

Alkermes (ALKS) Q4 2025 Earnings Call Transcript

Via The Motley Fool

Topics Earnings

Alkermes plc Reports Financial Results for the Fourth Quarter and Year Ended Dec. 31, 2025 and Provides Financial Expectations for 2026

February 25, 2026

From Alkermes plc

Via Business Wire

Alkermes plc Announces CEO Succession Plan

February 25, 2026

From Alkermes plc

Via Business Wire

Alkermes to Present at the TD Cowen 46th Annual Health Care Conference

February 24, 2026

From Alkermes plc

Via Business Wire

< Previous 1 2 3 4 5 6 7 8 9

...

12 13 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.